Data completeness
2/8 — Basic
MEPROBAMATE (meprobamate) by Pasithea Therapeutics is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Meprobamate is an oral tablet anxiolytic agent belonging to the carbamate class, indicated for short-term relief of anxiety symptoms. It acts on multiple CNS sites including the thalamus and limbic system to reduce anxiety. This pre-launch formulation from Pasithea Therapeutics targets patients with anxiety disorders seeking non-benzodiazepine treatment options.
Pre-Launch
Early-stage product with undefined commercial trajectory; team composition and headcount will depend heavily on regulatory outcomes and go-to-market strategy.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROBAMATE at Pasithea Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.